Kilitch Drugs (India) Ltd.

389.95 -0.25 ▼-0.1%

28 March 2024, 04:01:00 PM
Volume: 2,533

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.kilitch.com
Market Cap 626.97 Cr.
Enterprise Value(EV) 646.34 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 9.06 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 43.03 Trailing Twelve Months Ending 2023-12
Industry PE 41.54 Trailing Twelve Months Ending 2023-12
Book Value / Share 105.19 Trailing Twelve Months Ending 2023-12
Price to Book Value 3.71 Calculated using Price: 389.85
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.61 Cr. 16,082,319 Shares
FaceValue 10
About Kilitch Drugs (India) Ltd.
Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch Drugs (India) Ltd. Delivery

Delivered Qty
Traded Qty

Kilitch Drugs (India) Ltd. Performance

1 Day
-0.06%
1 Week
+10.78%
1 Month
-6.99%
3 Month
+4.03%
6 Month
+57.24%
1 Year
+168.47%
2 Year
+132.04%
5 Year
+103.42%
10 Year
+2066.39%

Kilitch Drugs (India) Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) -0.25 -9.91 -8.59 4.95 3.36 0.71 3.09 4.73 5.86
Return on Capital Employed (%) -0.74 -10.11 -8.69 6.08 7.59 1.95 4.4 7.26 10.26
Return on Assets (%) -0.19 -9.25 -7.86 4.36 2.85 0.59 2.19 3.03 3.89

Kilitch Drugs (India) Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 120 109 101 112 121 118 127 139 152 167
Non Curr. Liab. -1 -1 -2 -2 -1 -1 -1 -1 -2 -3
Curr. Liab. 7 8 12 15 20 22 73 69 69 70
Minority Int. 1 2 2 2 1 -1 -1
Equity & Liab. 126 116 110 126 143 142 202 208 218 234
Non Curr. Assets 79 68 62 63 78 86 122 94 91 91
Curr. Assets 47 47 49 63 65 56 80 114 126 144
Misc. Exp. not W/O 0 0
Total Assets 126 116 110 126 143 142 202 208 218 234

Kilitch Drugs (India) Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 19 21 29 51 82 53 69 114 140 155
Other Income 3 3 1 3 5 5 3 3 3 5
Total Income 22 24 30 54 88 58 71 117 143 160
Total Expenditure -21 -25 -29 -46 -76 -53 -63 -104 -122 -132
PBIDT 1 -2 1 9 11 5 8 13 21 28
Interest 0 0 0 0 -1 -1 -1 -1 -5 -6
Depreciation -2 -10 -10 -2 -2 -2 -2 -2 -4 -3
Taxation 1 0 0 -1 -5 -1 -1 -3 -4 -6
Exceptional Items
PAT 0 -11 -9 5 4 1 4 6 8 13
Minority Interest 0 1 2 2
Share Associate
Other Related Items
Consolidated Net Profit 0 -11 -9 5 4 1 4 7 10 15
Adjusted EPS 0 -8 -7 4 2 1 2 5 7 9

Kilitch Drugs (India) Ltd. Cash Flow

Particulars 10 years 2012-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. -29 -8 17 1 1 0 4 46 6 3
Cash Fr. Inv. 41 -31 -20 -2 -4 -14 -10 -38 -15 8
Cash Fr. Finan. -9 0 0 0 6 17 1 2 7 -1
Net Change 2 -39 -2 0 2 3 -5 10 -2 10
Cash & Cash Eqvt 12 5 3 2 5 8 3 13 10 20

Kilitch Drugs (India) Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 68.25 68.25 68.25 68.25 68.25 68.25 68.25 69.23 69.23
Public 31.75 31.75 31.75 31.75 31.75 31.75 31.75 30.77 30.77
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Kilitch Drugs (India) Ltd. Announcements

Tue, 26 Mar 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We hereby inform you that we have received intimation from RTA regarding loss of share certificate by Ms. Nitaben Shah
Tue, 26 Mar 2024
Closure of Trading Window
The trading window for dealing in securities of the Company will remain closed for all the designated person of the Company and their immediate relatives with effect from Monday 1st April 2024 till expiry of 48 hours after declaration of the financial results for the quarter ended 31st March 2024
Thu, 21 Mar 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate as per intimation received from RTA

Kilitch Drugs (India) Ltd. Technical Scans

Thu, 28 Mar 2024
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Above Last Week High Close Above Last Week High
High Increase in 6 Months High Increase in 6 Months

Kilitch Drugs (India) Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 388,812.23 1,620.50 +0.8%
Cipla Ltd. 120,673.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. 102,679.14 6,171.85 +2.0%
Zydus Lifesciences Ltd. 101,151.67 1,007.35 +0.8%
Mankind Pharma Ltd. 92,029.19 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. 91,330.58 6,347.35 +1.9%
Divi's Laboratories Ltd. 91,234.91 3,452.55 +2.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 43.66 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 32.54 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.64 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 34.01 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 53.29 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.71 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 65.97 3,452.55 +2.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.23 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-12 4.66 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.82 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.37 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-12 10.36 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.52 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-12 7.00 3,452.55 +2.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 0.02 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 12.85 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,452.55 +2.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,452.55 +2.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,620.50 +0.8%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,494.65 +1.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,171.85 +2.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 1,007.35 +0.8%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,300.75 -1.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,347.35 +1.9%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,452.55 +2.6%

Kilitch Drugs (India) Ltd. FAQ's

What is Kilitch Drugs(India) share price?

Can I buy Kilitch Drugs(India) shares now?

What is the Market Cap of Kilitch Drugs(India)?

What are the key metrics to analyse Kilitch Drugs(India)?

What is the 52 Week High and Low of Kilitch Drugs(India)?

What is the trend of Kilitch Drugs(India) share price?